• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Lansforsakringar AB (publ) Dec 10 Product Image

Lansforsakringar AB (publ) Dec 10

  • ID: 2024306
  • December 2010
  • Standard & Poors

Diversified income streams from non-life insurance and banking subsidiaries, complemented by track record of support from owners. Strong debt-servicing ability within the L-nsf-rs-kringar Alliance. Concentration of business predominantly in the Swedish market. The counterparty credit rating on Sweden-based L-nsf-rs-kringar AB (publ) (LF AB) reflects its core status within L-nsf-rs-kringsgruppen, known as the L-nsf-rs-kringar Alliance (the Alliance), as well as its role as the intermediate holding company for the Alliance. LF AB is jointly owned by the 24 regional mutual insurance companies that make up the Alliance, and it is regarded as structurally subordinated to the policyholder obligations of the Alliance. The strong financial strength of the Alliance derives from its leadership in the Swedish non-life market, strong capitalization, and strong,...

Companies mentioned in this report are: Lansforsakringar AB
Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown

Lansforsakringar AB

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.